Disc Medicine

Disc Medicine

  • Founded: 2017
  • Location: Cambridge, MA
  • Employee range: 11 - 50
  • Clinical stage: Clin2
  • Therapy area: Erythropoietic porphyrias (ODD)
  • Drug types: HEM, RAR, GEN, ONC
  • Lead product: Bitopertin
  • Product link: https://www.discmedicine.com/our-pipeline/
  • Funding: $137M Jun 2023; $62.5M stock Feb 2023; $90M B Sep 2021; $50M A Oct 2019
  • Investors: Atlas Venture



job board

Short description:

Drugs to regulate hepcidin expression within the body

Drug notes:

DISC-0974 Clin1b/Clin2 anemia of myelofibrosis, Clin0 anemia of CKD, undisclosed; MWTX-003 Clin0 beta-thalassemia, polycythemia vera

Long description:

Disc Medicine is developing therapies for rare blood diseases. Red blood cells have a characteristic disc shape that facilitates their role in oxygen transport, however, there are millions of patients whose lives are affected by hematologic diseases. Disc medicine is focusing on the fundamentals, heme and iron, that are important for red blood cell function to develop effective therapies. In particular, Disc’s main programs are designed to modulate heme biosynthesis and iron metabolism which is supported by genetic or clinical evidence. Bitopertin, Disc’s lead compound, is an oral, selective inhibitor of glycine transporter 1 and now being tested in Phase 2 clinical trials.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy

Contact: recruit@workinbiotech.com